Equity Profile

KYMR

Kymera Therapeutics, Inc.

Health CareBiotechnology$9.5B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to treat diseases by harnessing the body's own immune system....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KYMR Q2-2026 Earnings Preview

Context

Company Snapshot

Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to treat diseases by harnessing the body's own immune system. With a market cap of $10 billion, it operates in the health care sector, which is seeing increased interest due to advancements in personalized medicine and targeted therapies.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-4.04%

Avg Stock Reaction

-3.15%

Last Quarter Recap

In Q1 2026, Kymera reported an EPS of -$0.71, which was better than the expected -$0.89, resulting in a positive surprise of 20.4%. However, there was no revenue reported, which leaves uncertainty about overall performance.

Management Promises & Guidance

Focus on advancing clinical trials for its drug candidates.
Commitment to improving operational efficiency.
Plans to enhance investor communication regarding pipeline developments.

Expectations

Wall Street Expectations

Overall expectations are mixed as the company has shown some ability to beat EPS estimates, but revenue remains uncertain. Investors are looking for signs of progress in its drug development pipeline.

Bull Case

If Kymera can demonstrate significant advancements in its clinical trials and provide positive updates on its drug candidates, it could lead to increased investor confidence and a higher stock price.

Bear Case

On the other hand, if the company fails to provide clarity on its revenue generation or if clinical trials do not yield promising results, it could lead to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What progress has been made in clinical trials for key drug candidates?

The market will closely watch for updates on clinical trial results, as successful outcomes could significantly impact future revenue potential.

Can management provide clarity on the timeline for revenue generation?

Understanding when the company expects to start generating revenue is crucial for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Kymera's drug candidates to advance successfully in clinical trials, leading to earlier-than-expected revenue generation.

Supporting Evidence

The company has a history of beating EPS estimates, indicating potential for positive surprises.

Options pricing suggests a high volatility expectation, which may not align with the actual performance of the stock in previous quarters.

Key Risk

If clinical trial results exceed expectations, it could lead to a significant upward revision in revenue forecasts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the company's ability to showcase progress in its drug development pipeline and clarify its revenue outlook.

Bull Confirmed If

Demonstrating a clear path to revenue generation with positive clinical trial results would confirm the bull case.

Bear Confirmed If

Failure to provide a timeline for revenue or disappointing trial results would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.64%

Historical Avg

±4.4%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±23.6% while KYMR has averaged ±4.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.0%

Calls (0)P/C Ratio: 1.00Puts (14K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kymera beats expectations and raises guidance, history suggests the stock could see an average one-day move of +2.16%, confirming bullish sentiment.

In-Line / Cautious

A cautious in-line report may lead to muted reactions, as investors await more definitive guidance on future growth.

Miss

If the company misses expectations, history suggests an average one-day move of -4.14%, indicating a potential sell-off.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Any guidance on expected timelines for revenue generation.
3Insights into operational efficiencies and cost management.
4Management's perspective on competitive landscape and market opportunities.
5Plans for future product development and pipeline expansion.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to treat diseases by harnessing the body's own immune system....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KYMR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-4.04%

Avg Stock Reaction

-3.15%

Last Quarter Recap

Management Promises & Guidance

Focus on advancing clinical trials for its drug candidates.
Commitment to improving operational efficiency.
Plans to enhance investor communication regarding pipeline developments.

Expectations

Wall Street Expectations

Bull Case

If Kymera can demonstrate significant advancements in its clinical trials and provide positive updates on its drug candidates, it could lead to increased investor confidence and a higher stock price.

Bear Case

On the other hand, if the company fails to provide clarity on its revenue generation or if clinical trials do not yield promising results, it could lead to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What progress has been made in clinical trials for key drug candidates?

The market will closely watch for updates on clinical trial results, as successful outcomes could significantly impact future revenue potential.

Can management provide clarity on the timeline for revenue generation?

Understanding when the company expects to start generating revenue is crucial for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Kymera's drug candidates to advance successfully in clinical trials, leading to earlier-than-expected revenue generation.

Supporting Evidence

The company has a history of beating EPS estimates, indicating potential for positive surprises.

Options pricing suggests a high volatility expectation, which may not align with the actual performance of the stock in previous quarters.

Key Risk

If clinical trial results exceed expectations, it could lead to a significant upward revision in revenue forecasts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the company's ability to showcase progress in its drug development pipeline and clarify its revenue outlook.

Bull Confirmed If

Demonstrating a clear path to revenue generation with positive clinical trial results would confirm the bull case.

Bear Confirmed If

Failure to provide a timeline for revenue or disappointing trial results would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.64%

Historical Avg

±4.4%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±23.6% while KYMR has averaged ±4.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.0%

Calls (0)P/C Ratio: 1.00Puts (14K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kymera beats expectations and raises guidance, history suggests the stock could see an average one-day move of +2.16%, confirming bullish sentiment.

In-Line / Cautious

A cautious in-line report may lead to muted reactions, as investors await more definitive guidance on future growth.

Miss

If the company misses expectations, history suggests an average one-day move of -4.14%, indicating a potential sell-off.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Any guidance on expected timelines for revenue generation.
3Insights into operational efficiencies and cost management.
4Management's perspective on competitive landscape and market opportunities.
5Plans for future product development and pipeline expansion.